Mechanistically, miRNA-148a, that was selectively encapsulated into CDCs-exosomes mediated the therapeutic effect of HHP-EXO to myocardial hypertrophy via down-regulation of the expression of GP130, leading to inhibition of STAT3, ERK1/2 and AKT signaling pathways. Here, MAPK3 is linked to hypertrophy.